For instance, miR-622 inhibits the expression of KRAS, leading to inhibition of the RAF/MAPK and PI3K/AKT pathways, suppression of HCC growth, and enhancement of sorafenib sensitivity (Dietrich et al., 2018). This evidence concerns the gene AKT1 and hepatocellular carcinoma.